Myriad Genetics is a leading molecular diagnostic company dedicated to saving lives and improving the quality of life for patients through the discovery and commercialization of novel, transformative diagnostic tests for several major diseases, including cancer, rheumatoid arthritis, diabetes and more. We are changing the way patients, healthcare professionals and researchers view disease by providing molecular and companion diagnostic tests that can be used to:
- Assess a person’s risk of developing disease
- Assist in making timely and accurate diagnoses
- Predict the risk of disease progression and recurrence
- Guide personalized treatment
Improving Patient Care Across a Full Spectrum of Diseases
Since discovering the BRCA1 gene in 1994 and launching BRACAnalysis®, the first full-length gene sequencing test for a major disease, in 1996, Myriad has been a pioneer in molecular diagnostics. The Company has been and continues to be a trailblazer in personalized medicine, expanding our offerings to include molecular and companion diagnostic tests used in the fields of oncology, preventive care, urology, dermatology, neuroscience and autoimmune diseases.
Our growing portfolio of clinically accurate and actionable tests is helping to save lives and improve the quality of life for patients at every step of their healthcare journey. Myriad tests are currently being used to improve the understanding and treatment of: